Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 20, 2004. The report serves as a notification of changes in directors' interests in the company's Ordinary Shares and does not contain a full financial performance review.
Key Financial Metrics
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity. The document is limited to reporting specific share transactions and does not include consolidated financial statements.
Material Changes
The filing details the following specific changes in share ownership:
- Employee Trust Transfer: On April 16, 2004, Abacus (GSK) Trustees Limited transferred 15,168 Ordinary Shares from the GlaxoSmithKline Employee Trust to participants in the SmithKline Beecham Employee Share Option Plan 1991.
- Director Share Increase: On April 20, 2004, Director Mr. J D Coombe increased his interest by 179 Ordinary Shares at a price of £11.61 per share. This increase resulted from the re-investment of the dividend paid to shareholders on April 15, 2004.
Guidance, Outlook, and Risks
The filing does not contain management commentary, financial guidance, outlook, risk factors, or contingencies. It strictly reports on the administrative changes in director and trust shareholdings.
Investor Verification Points
- Verify the total number of shares held by the GlaxoSmithKline Employee Trust following the April 16 transfer.
- Confirm the updated shareholding balance for Director Mr. J D Coombe post-dividend reinvestment.
- Note that this filing does not reflect operational or financial performance for the period; refer to Form 20-F for comprehensive financial data.